➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Medtronic
Dow
Mallinckrodt
McKesson

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Zabofloxacin

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Zabofloxacin?

Zabofloxacin is an investigational drug.

There have been 4 clinical trials for Zabofloxacin. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2012.

The most common disease conditions in clinical trials are Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive, and Lung Diseases. The leading clinical trial sponsors are Dong Wha Pharmaceutical Co. Ltd., Wonju Severance Christian Hospital, and Incheon St.Mary's Hospital.

There are three US patents protecting this investigational drug and twenty-seven international patents.

Recent Clinical Trials for Zabofloxacin
TitleSponsorPhase
Evaluation of Pharmacokinetics Profiles and Bactericidal Activity of ZabofloxacinDong Wha Pharmaceutical Co. Ltd.Phase 1
A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mgAjou UniversityPhase 3
A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mgAsan Medical CenterPhase 3

See all Zabofloxacin clinical trials

Clinical Trial Summary for Zabofloxacin

Top disease conditions for Zabofloxacin
Top clinical trial sponsors for Zabofloxacin

See all Zabofloxacin clinical trials

US Patents for Zabofloxacin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Zabofloxacin   Start Trial Quinolone carboxylic acid derivatives Dong Wha Pharmaceutical Industrial Co., Ltd. (Seoul, KR)   Start Trial
Zabofloxacin   Start Trial Quinolone carboxylic acid derivatives Dong Wha Pharmaceutical Industrial Co., Ltd. (Seoul, KR)   Start Trial
Zabofloxacin   Start Trial Aspartate of 1-cyclopropyl-6-fluoro-7-(8-methoxyimino-2,6-diaza-spiro[3.4]oct-6-yl)-4-- oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid, method for preparing the same, and antimicrobial pharmaceutical composition comprising the same Dong Wha Pharmaceutical Co. Ltd. (Seoul, KR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Zabofloxacin

Drugname Country Document Number Estimated Expiration Related US Patent
Zabofloxacin Australia 7940598 2017-06-26   Start Trial
Zabofloxacin China 1114607 2017-06-26   Start Trial
Zabofloxacin China 1259952 2017-06-26   Start Trial
Zabofloxacin Germany 69802692 2017-06-26   Start Trial
Zabofloxacin European Patent Office 0994878 2017-06-26   Start Trial
Zabofloxacin Japan 2000513378 2017-06-26   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Medtronic
Dow
Mallinckrodt
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.